GlassScriptPhysician profile
Walter D Kucaba
NPI 1881787802
$3,486.87
in general payments reported to CMS, 2019-2025
24 companies · $1,026 in 2025
The $1,026 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $178 · 2020: $11.47 · 2021: $174 · 2022: $402 · 2023: $678 · 2024: $1,016 · 2025: $1,026.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,720.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,720.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $610.79 | 2021-2025 | |
| Novo Nordisk INC | $512.46 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $336.79 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $334.70 | 2019-2025 | |
| Exact Sciences Corporation | $234.77 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $219.10 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2, Octrode |
| Kowa Pharmaceuticals America, INC. | $218.13 | 2025 | Zoryve |
| Bayer Healthcare Pharmaceuticals INC. | $216.24 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $150.49 | 2022-2025 | |
| Amgen INC. | $110.87 | 2019-2025 | Repatha, Otezla, Evenity |
| Dexcom, INC. | $96.51 | 2021-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $69.62 | 2019-2024 | Veozah |
| Axsome Therapeutics, INC. | $62.75 | 2025 | Auvelity, Symbravo |
| Lilly USA, LLC | $53.90 | 2019-2024 | Zepbound, Mounjaro |
| Phathom Pharmaceuticals, INC. | $51.41 | 2024-2025 | Voquezna |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $43.80 | 2019-2023 | Trelegy Ellipta, Arexvy |
| Daiichi Sankyo INC. | $42.70 | 2019-2024 | Injectafer |
| Esperion Therapeutics, INC. | $30.22 | 2022-2024 | Nexletol |
| Lundbeck LLC | $17.27 | 2025 | Rexulti |
| Medtronic, INC. | $16.92 | 2024 | Intellis Adaptivestim |
| Merck Sharp & Dohme LLC | $16.29 | 2024 | Gardasil 9, Vaxelis, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.37 | 2025 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $13.02 | 2022 | |
| Sanofi-Aventis U.S. LLC | $12.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Kucaba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.